Wire · opportunities
SaaS Platforms Gain Traction in Clinical Trials Despite Spreadsheet Reliance
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
87% of clinical trial sites now run decentralized studies but rely on spreadsheets for management; SaaS platforms are gaining adoption by offering real-time dashboards and centralised monitoring at subscription cost, though sponsors retain full regulatory accountability for data integrity and compliance regardless of vendor certification.
This Wire brief sits within Fusion42's coverage of Digital Health and Enterprise Software. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
If you're building clinical trial software, your real customer is the 15-person biotech that can't afford a CRO's data infrastructure — but your liability for FDA and 21 CFR Part 11 compliance never leaves the sponsor, so clean data models and interoperability with regulatory submissions are your only defensible moat, not feature count.
◆ Related on Wire
◆ Topics